Hormone-refractory prostate cancer
RecruitingStudy Comparing Docetaxel and Androgen Receptor-Targeted Agents (Abiraterone or Enzalutamide) for Patients with Metastatic Castration-Resistant Prostate Cancer
Study Comparing Docetaxel and Androgen Receptor-Targeted Agents (Abiraterone or Enzalutamide) for Patients with Metastatic Castration-Resistant Prostate Cancer
- Disease:Hormone-refractory prostate cancer
- Substances:AbirateroneDocetaxel+1
Italy- Participants:18–64 years · 65+ years
- Substances:Abiraterone
- Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS








